Neoadjuvant and Adjuvant Immunotherapy is named as a drug or biological intervention in 2 clinical trials in our China trial register, 2 of which are recruiting. Lead sponsors include Rui You (1) and Ming-Yuan Chen (1). Registered phases: Phase 2 and Phase 3. Conditions studied include Locally Advanced Head and Neck Squamous Cell Carcinoma.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07524452 | Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (ClinicalTrials.gov ↗) Locally Advanced Head and Neck Squamous Cell Carcinoma |
Phase 3 | Recruiting |
| NCT07371234 | Low-Dose Radiotherapy and Anti-PD-1 Immunotherapy as Neoadjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (ClinicalTrials.gov ↗) Locally Advanced Head and Neck Squamous Cell Carcinoma |
Phase 2 | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Locally Advanced Head and Neck Squamous Cell Carcinoma | 2 |
| Lead sponsor | Trials |
|---|---|
| Rui You | 1 |
| Ming-Yuan Chen | 1 |
| Register | Neoadjuvant and Adjuvant Immunotherapy trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Neoadjuvant and Adjuvant Immunotherapy works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Neoadjuvant and Adjuvant Immunotherapy (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.